In individuals with Alzheimer’s disease Zn(II) would bind to the ferroxidase site in the E2 domain of APP and inhibits its ferroxidase activity, resulting in accumulation of intracellular Fe(II) and subsequent oxidative damage of the cells. Here, APP is linked to early-onset autosomal dominant Alzheimer disease.